"Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further improvement in EBIT and continued high gross margins. Devyser's transplant products were given IVDR approvals during the quarter and
Fredrik Alpsten, CEO, Devyser
The quarter from July to
- Net sales amounted to
SEK 46.7 million (31.2), corresponding to a 49.8 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 37.7 percent. -
Gross profit totaled
SEK 39.6 million (26.3), equal to a gross margin of 85.0 percent (84.4). -
Operating profit (EBIT) amounted to
SEK -7.8 million (-8.2). -
Profit after tax totaled
SEK -6.0 million (-8.8). -
Earnings per share before and after dilution amounted to
SEK -0.37 (-0.55). -
Cash flow from operating activities stood at
SEK -13.9 million (-11.8).
The period from January to
- Net sales amounted to
SEK 123.9 million (92.4), corresponding to a 34.1 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 24.0 percent. -
Gross profit totaled
SEK 104.8 million (76.2), corresponding to a gross margin of 84.6 percent (82.5). -
Operating profit (EBIT) amounted to
SEK -40.4 million (-26.0). -
Profit after tax totaled
SEK -40.5 million (-29.3). -
Earnings per share before and after dilution amounted to
SEK -2.51 (-1.84). -
Cash flow from operating activities stood at
SEK -56.0 million (-27.1).
Important events during the quarter
IVDR approvals of Devyser's transplant products
Devyser's test for the detection of donor-derived cell-free DNA in blood samples from kidney transplant patients, and the company's product for the follow-up of stem cell transplant patients, were given IVDR approvals in July.
Expanded collaboration with
Devyser and
Devyser and
Devyser and
Important events after the end of the quarter
No significant events have occurred since the end of the quarter.
Presentation
The report will be presented at an audiocast at
https://conference.financialhearings.com/teleconference/?id=5003819
The presentation will also be webcast and can be accessed from the following web address:
https://ir.financialhearings.com/devyser-diagnostics-q3-report-2023
This report and previous financial reports are available on the company's webpage https://investors.devyser.com/en/reports-presentations.
This information is information that
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 673 106
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502
About
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for complex genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.
Devyser was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
For more information, visit www.devyser.com.
https://news.cision.com/devyser-diagnostics-ab/r/devyser-diagnostics-ab-publishes-quarterly-report-for-july-to-september-2023,c3872178
https://mb.cision.com/Main/13649/3872178/2417772.pdf
(c) 2023 Cision. All rights reserved., source